Blh Pharmaceuticals Inc.

Blh Pharmaceuticals Inc. specializes in single-use scar-management dressings, specifically products designed to aid skin healing and reduce scarring. Their primary focus is on topical solutions like Vitamin E-infused sheets, which are applied directly to wounds during recovery to support tissue repair.

Blh Pharmaceuticals Inc. is headquartered in the United States, which means its devices are subject to FDA regulations. Since their products fall under FDA Class I classification, they are considered low-risk and typically require less stringent premarket review, though compliance with UDI requirements (like listing in the FDA’s UDI database) remains mandatory for traceability and transparency.

Blh Pharmaceuticals Inc.’s devices are included in the FDA’s Unique Device Identifier (UDI) database, a publicly accessible registry that ensures traceability and compliance tracking for medical products. This listing helps healthcare providers and regulators verify device details like manufacturer information, model names, and batch identifiers.

Blh Pharmaceuticals Inc.’s devices are classified as FDA Class I, which means they pose minimal risk to patients and generally do not require premarket approval. This classification simplifies regulatory pathways but still requires adherence to good manufacturing practices (GMP) and UDI compliance. The classification reflects the company’s focus on low-risk, single-use scar-management products like Vitamin E sheets.